The case for & against
Bull & Bear analysis
Bullish
Compass Therapeutics, Inc. (NASDAQ: CMPX) is a biotechnology firm specializing in innovative cancer therapies, particularly bispecific antibodies that target immune checkpoint pathways. The company is focused on addressing unmet medical needs in oncology with its lead candidate, Tevesimig, aiming to improve outcomes for patients with advanced biliary tract cancer. Compass Therapeutics is positioning itself strongly within the burgeoning area of immunotherapy which is a significant theme in the ongoing transformation of cancer treatment paradigms.
Bull says
- ↑Tevesimig achieved 17.1% overall response rate and >20% survival, outperforming controls
- ↑Analyst consensus is Moderate Buy with $12.25 target implying 425.8% upside
- ↑$101M cash runway provides funding through 2027 for trials
- ↑Engaging FDA for breakthrough designation to accelerate Tevesimig approval
- ↑Strong 13F institutional backing and low volatility attract investors
- ↑Rising demand for innovative immunotherapies supports long-term market growth
Bear says
- ↓Earnings Yield of –2.38% and weak profitability score signal financial strain
- ↓Revisions sentiment is negative, with PFS/OS analysis pushed to Q1 2026
- ↓High crossover rate in trials may skew overall survival results
- ↓Competition from Bristol-Myers Squibb and Merck limits market share
- ↓Uncertain FDA breakthrough pathway amid delayed regulatory timelines
- ↓Negative size factor and elevated volatility suggest structural headwinds
Investment themes with CMPX
Biotech↓ -3.20%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 07-14-2026bullish
Transcript signals
Bull points
- there are currently fewer total deaths in the study than we have projected
- More patients are alive today than we have projected
- a 17.1% overall response rate, about tripling what was seen in the control arm with a p-value of 0.031
Read full transcript analysis ›